Matthew Goetz, MD
Enriched profileProfessor of Oncology and Pharmacology; Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D.; Enterprise Deputy Director of Translational Research, Mayo Clinic Cancer Center · Mayo Clinic
Matthew Goetz is Professor of Oncology and Pharmacology; Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D.; Enterprise Deputy Director of Translational Research, Mayo Clinic Cancer Center at Mayo Clinic. OpenAlex indexes 1,146 publications with 36,210 citations (h-index 86); ClinicalTrials.gov lists 17 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 21 Oct 2026
Matthew Goetz, M.D., is Professor of Oncology and Pharmacology at Mayo Clinic. The public record shows 1,146 publications with 36,210 citations (h-index 86), centered on Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Estrogen and related hormone effects. It also documents an investigator role on 17 registered clinical trials, industry payments reported by 14 companies, 3 NIH-funded awards (2008–2026).
- Most recent indexed publication: 2026 · Nature communications
- Top research focus: Breast Cancer Treatment Studies
- 17 registered trials on ClinicalTrials.gov
- Open Payments reporting from 14 companies
Generated from the cited public record · current as of 21 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 35 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 291.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 21 Oct 2026
Listed as an investigator on 17 registered studies on ClinicalTrials.gov. The most recent:
- Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Sponsor: Washington University School of Medicine
Industry payments
Updated 21 Oct 2026
14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Lilly USA, LLCProgram year20254 payments$18,000openpaymentsdata.cms.gov ↗
- Genentech, Inc.Program year20253 payments
- Eli Lilly and CompanyProgram year20255 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
69.8%PD-1 inhibitor28.9%Pembrolizumab100%Part B, office-administered≥17 patientsCD38-directed Cytolytic Antibody23.2%Daratumumab100%Part B, office-administered≥16 patients+ 4 more classes in this area
Metabolism & gastrointestinal
26.3%Other antiemetics21.7%Fosaprepitant100%Part B, office-administered≥17 patientsSerotonin-3 Receptor Antagonist4.6%Palonosetron hcl59%Ondansetron hydrochloride41%Part B, office-administered≥31 patientsSensory organs
3.7%Corticosteroid3.7%Dexamethasone sodium phosphate100%Part B, office-administered≥38 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 21 Oct 2026
3 NIH research awards on record, funded 2008–2026 per NIH RePORTER. The latest:
Congress activity
Updated 21 Oct 2026
279 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ENDO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 1200: Spatially resolved tumor-cell MHC class II shapes adaptive immunity and therapeutic response in triple-negative breast cancer.
AACR Annual Meeting
AACR2026Co-author - Abstract 1401: A novel statistical framework for surrogate endpoint prediction of survival in neoadjuvant breast cancer trials.
AACR Annual Meeting
AACR2026Co-author - Abstract 2293: The LncRNA XIST mediates resistance to estrogen receptor beta targeted therapies in triple negative breast cancer
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 21 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase Cβ.
Nature communications
Article2026 - CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.
NPJ breast cancer
Article2025 - Reply to: "Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer" and "CDK4/6 Inhibitors in Estrogen Receptor-Low Breast Cancer".
Journal of clinical oncology
Article2025 - Endocrine Therapy Omission in Estrogen Receptor-Low (1%-10%) Early-Stage Breast Cancer.
Journal of clinical oncology
Article2025
Most-cited works
by citation count (OpenAlex)- 01Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerArticle2,388 citations2018
- 02MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast CancerArticle1,734 citations2017
- 03Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in OncologyArticle1,609 citations2018
- 04Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyArticle1,585 citations2020
- 05Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyArticle952 citations2022
Network
Updated 21 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 21 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/matthew-goetz-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
breastcancer.org/bio/matthew-goetz
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →breastcancer.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 21 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →practiceupdate.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →orcid.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →webarchive.org ↗
- Abstract Reviewer and Abstract Review Section Chair
San Antonio Breast Cancer Symposium Program Committee
2016provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗ - Chair
Mayo Breast Cancer Research Group
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗ - Co-leader
Women's Cancer Program, Mayo Clinic Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗ - Co-Investigator Principal
Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE) grant
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗ - Co-Chair
San Antonio Breast Cancer Symposium Program Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗
Media & interviews
press, podcasts and appearances- Podcast episode: 'The Clinical Implications of Key Recent Data Sets in Breast Cancer,' November 16
2022, with Dr. Ian Krop
2022provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podwise.ai ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
Ayalew Tefferi, MD
Mayo Clinic
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope